Travere Soars After FILSPARI Wins FDA Approval for FSGS Treatment
Travere Therapeutics stock climbed 44% after the FDA approved FILSPARI to reduce proteinuria in adults and children aged 8 and above with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is now the first FDA-approved therapy for FSGS and expands the drug's label beyond IgA nephropathy. Clinical trial data and a…